Perrigo Hopes To Retain Lead From Leiner Woes, Eyes Private Label Zyrtec
This article was originally published in The Tan Sheet
Executive Summary
Prompted by the sudden voluntary suspension of Leiner Health Product's U.S. OTC operations, private labeler Perrigo is looking to maintain its increased market share via key adjustments in its production processes to meet high customer demand